Objective: Benzodiazepine immediate‐use seizure medications (ISMs; also called rescue therapies) are used to treat seizure clusters/acute repetitive seizures in patients with epilepsy. In the United States, diazepam nasal spray is an approved ISM for patients ≥2 years of age. The primary objective was to assess diazepam nasal spray pharmacokinetics (PK) in patients 2–5 years of age; safety and tolerability were secondary objectives.Methods: This Phase 1/2a, open‐label, single‐dose, PK study with a 180‐day open‐label safety period enrolled patients with epilepsy 2–5 years of age. Diazepam nasal spray (0.5‐mg/kg per diazepam rectal gel dosing) was administered by a medical professional, followed by PK sampling. During the safety period, caregivers administered diazepam nasal spray as needed for frequent or acute repetitive seizures. Seizures and dosing were recorded in a diary. Study visits included safety evaluations. Use of second doses was a proxy for effectiveness.Results: Thirty‐six patients were enrolled, with 35 in the PK population. PK parameters and modeling were comparable to older children and adults, confirming that diazepam nasal spray was readily absorbed and supporting the adequacy of the 0.5‐mg/kg dose for this age group. In the open‐label period, second doses within 24 h of the initial dose were administered for 16.3% of seizure events (37/227), indicating that a second dose was not used for most seizure events (83.7%). Treatment‐related treatment‐emergent adverse events occurred in seven patients (19.4%); all were mild except one (moderate). There was one report each of respiratory depression and respiratory distress; neither was treatment related.Significance: This study characterizes the PK of diazepam in patients 2–5 years of age and reports a safety profile consistent with older patients. Results demonstrate that the diazepam nasal spray drug–device combination is appropriate for drug delivery and absorption in these patients.
22 February 2026 in Journal of Inherited Metabolic Disease
Aromatic ʟ‐amino acid decarboxylase (AADC) deficiency is a rare pediatric neurotransmitter disorder that typically necessitates lifelong care, and that carries a risk of childhood mortality. Eladocagene exuparvovec gene therapy is designed to restore AADC production. Study GT‐002 (NCT04903288) is a phase 2, multicenter, open‐label trial assessing the pharmacodynamics, safety, and efficacy of eladocagene exuparvovec administered to the putamen bilaterally in pediatric patients with AADC deficiency using a magnetic resonance (MR)‐compatible cannula. Patients received eladocagene exuparvovec at 1.8 × 10 11 vector genomes via the SmartFlow MR‐compatible cannula in a single operative session. Endpoints include the change from baseline in cerebrospinal fluid homovanillic acid levels, motor milestone achievement, and safety. Here we report results from 48 weeks of follow‐up. Mean (SD) cerebrospinal fluid homovanillic acid levels increased from baseline (22.5 [32.3] nmol/L; n = 13) to week 48 (55.3 [45.6] nmol/L; change from baseline: 28.3 [13.7] nmol/L; p = 0.0003; n = 9), indicating de novo dopamine production. At baseline ( n = 13), all patients showed severe motor developmental delay; at week 48 ( n = 12), nine achieved full head control, four could sit unassisted, two could stand with support, and two could walk independently to a toy. Overall, 260 treatment‐emergent adverse events were reported in 13 patients; 259 were deemed unrelated and one likely unrelated to the MR‐compatible cannula. No treatment‐emergent adverse events led to study withdrawal and no deaths occurred. This study provides further evidence of the favorable pharmacodynamic, efficacy, and safety profile of eladocagene exuparvovec in children with AADC deficiency; intraputaminal administration using an MR‐compatible cannula was well tolerated. Study GT‐002 (NCT04903288) provides further evidence of the favourable pharmacodynamic, efficacy and safety profile of eladocagene exuparvovec gene therapy in children with AADC deficiency over 48 weeks and demonstrates that intraputaminal administration using an MR‐compatible cannula was well tolerated, allowing for real‐time MRI confirmation of cannula placement and infusate coverage, and for accurate dosing to the putamen.